Conditions: Chronic Obstructive Pulmonary Disease
Keywords: Chronic obstructive pulmonary disease COPD
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 194
Healthy volunteers: no

Brief summary:
This study is designed to assess the effect of QVA149 (110/50 ug q.d.) versus placebo on pulmonary function and average physical activity levels in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).

Detailed description:

Arms:
arm 1: QVA149 once a day during 21 days cross-over to placebo once a day for up to 21 days arm 2: Placebo once a day during 21 days cross-over to QVA149 once a day for 21 days

Interventions: intervention 1: QVA149 intervention 2: Placebo
Intervention descriptions: intervention 1: QVA149 (110/50 µg) once a day via Breezhaler® device intervention 2: Placebo once a day via Breezhaler® device

Protocol document: